The FDA has moved to exclude semaglutide, tirzepatide and liraglutide -- which are in several popular weight loss drugs -- ...

The U.S. Food and Drug Administration on Wednesday approved a second oral GLP-1 medication, giving adults eligible for weight loss medication another option. The new pill, called Foundayo, is made by ...

If that proposal is finalized, the exclusion would likely limit the mass compounding of those medicines ​unless they appear ...

The U.S. Food and Drug Administration approved Zepbound, a new weight loss drug from pharmaceutical company Eli Lilly, on Wednesday. Zepbound is a once-weekly injectable medication with an active ...

Semaglutide, the key ingredient in Novo Nordisk’s Wegovy and Ozempic, and Tirzepatide, sold by Eli Lilly as Zepbound and Mounjaro, would be excluded from bulk compounding. ・The 503B Bulk List features ...

After just a few weeks on the market, thousands are already on Foundayo, Eli Lilly's oral weight loss pill. The drugmaker is ...

While GLP-1 medications first gained visibility for diabetes care and later for weight loss, researchers are now evaluating ...

It is the fastest approval of a new type of drug, known as a new molecular entity, since 2002, the FDA said. Foundayo is ...

Drugmakers continue to test weight-loss medicines against dummy pills and shots, even with a growing number of effective ...

The FDA has proposed excluding certain active ingredients used in weight-loss drugs from Novo Nordisk and Eli Lilly on the ...

A new version of the popular diabetes treatment Mounjaro can be sold as a weight-loss drug, U.S. regulators announced Wednesday. The U.S. Food and Drug Administration approved Eli Lilly's drug, named ...